Endotoxin-induced endothelial fibrosis is dependent on expression of transforming growth factors β1 and β2

Infection and Immunity

Volumn 82, Issue 9, 2014, Pages 3678-3686

  Echeverría, César ^a,b   Montorfano, Ignacio ^a   Tapia, Pablo ^c   Riedel, Claudia ^a   Cabello Verrugio, Claudio ^a   Simon, Felipe ^a,d  

^a UNIVERSIDAD ANDRÉS BELLO   (Chile)

^b UNIVERSIDAD BERNARDO O'HIGGINS   (Chile)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^d Pontificia Universidad Católica de Chile   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ENDOTOXIN; FIBRONECTIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; VASCULAR ENDOTHELIAL CADHERIN;

ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; ENDOTOXEMIA; ENDOTOXIN INDUCED ENDOTHELIAL FIBROSIS; ENZYME ACTIVATION; FIBROSIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR DISEASE;

ACTINS; ANTIGENS, CD; CADHERINS; CELLS, CULTURED; COLLAGEN; DOWN-REGULATION; ENDOTHELIAL CELLS; ENDOTOXINS; FIBRONECTINS; FIBROSIS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

EID: 84906070153     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.02158-14     Document Type: Article

References (34)

1. Pinsky MR. 2004. Dysregulation of the immune response in severe sepsis. Am. J. Med. Sci. 328:220-229. http://dx.doi.org/10.1097/00000441-200410000-00005.
2. Rivers EP, Ahrens T. 2008. Improving outcomes for severe sepsis and septic shock: tools for early identification of at-risk patients and treatment protocol implementation. Crit. Care Clin. 24(Suppl 3):S1-S47. http://dx.doi.org/10.1016/j.ccc.2008.04.002.
3. Grandel U, Grimminger F. 2003. Endothelial responses to bacterial toxins in sepsis. Crit. Rev. Immunol. 23:267-299. http://dx.doi.org/10.1615/CritRevImmunol.v23.i4.20.
4. Schletter J, Heine H, Ulmer AJ, Rietschel ET. 1995. Molecular mechanisms of endotoxin activity. Arch. Microbiol. 164:383-389. http://dx.doi.org/10.1007/BF02529735.
5. Huet O, Dupic L, Harrois A, Duranteau J. 2011. Oxidative stress and endothelial dysfunction during sepsis. Front. Biosci. 16:1986-1995. http://dx.doi.org/10.1007/978-0-387-92278-2_6.
6. Dauphinee SM, Karsan A. 2006. Lipopolysaccharide signaling in endothelial cells. Lab. Invest. 86:9-22. http://dx.doi.org/10.1038/labinvest.3700366.
7. Simon F, Fernandez R. 2009. Early lipopolysaccharide-induced reactive oxygen species production evokes necrotic cell death in human umbilical vein endothelial cells. J. Hypertens. 27:1202-1216. http://dx.doi.org/10.1097/HJH.0b013e328329e31c.
8. Matsuda N, Hattori Y. 2007. Vascular biology in sepsis: pathophysiological and therapeutic significance of vascular dysfunction. J. Smooth Muscle Res. 43:117-137. http://dx.doi.org/10.1540/jsmr.43.117.
9. Echeverria C, Montorfano I, Sarmiento D, Becerra A, Nunez-Villena F, Figueroa XF, Cabello-Verrugio C, Elorza AA, Riedel C, Simon F. 2013. Lipopolysaccharide induces a fibrotic-like phenotype in endothelial cells. J. Cell. Mol. Med. 17:800-814. http://dx.doi.org/10.1111/jcmm.12066.
10. Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R. 2007. Discovery of endothelial to mesenchymal transition as a source for carcinomaassociated fibroblasts. Cancer Res. 67:10123-10128. http://dx.doi.org/10.1158/0008-5472.CAN-07-3127.
11. Potenta S, Zeisberg E, Kalluri R. 2008. The role of endothelial-tomesenchymal transition in cancer progression. Br. J. Cancer 99:1375-1379. http://dx.doi.org/10.1038/sj.bjc.6604662.
12. Lebrin F, Deckers M, Bertolino P, Ten Dijke P. 2005. TGF-beta receptor function in the endothelium. Cardiovasc. Res. 65:599-608. http://dx.doi.org/10.1016/j.cardiores.2004.10.036.
13. Santibanez JF, Quintanilla M, Bernabeu C. 2011. TGF-beta/TGF-beta receptor system and its role in physiological and pathological conditions. Clin. Sci. (Lond.) 121:233-251. http://dx.doi.org/10.1042/CS20110086.
14. Medici D, Potenta S, Kalluri R. 2011. Transforming growth factor-beta2 promotes Snail-mediated endothelial-mesenchymal transition through convergence of Smad-dependent and Smad-independent signalling. Biochem. J. 437:515-520. http://dx.doi.org/10.1042/BJ20101500.
15. Maleszewska M, Moonen JR, Huijkman N, van de Sluis B, Krenning G, Harmsen MC. 2013. IL-1β and TGFβ2 synergistically induce endothelial to mesenchymal transition in an NFκB-dependent manner. Immunobiology 218:443-454. http://dx.doi.org/10.1016/j.imbio.2012.05.026.
16. Morales MG, Vazquez Y, Acuna MJ, Rivera JC, Simon F, Salas JD, Alvarez RJ, Brandan E, Cabello-Verrugio C. 2012. Angiotensin IIinduced pro-fibrotic effects require p38MAPK activity and transforming growth factor beta 1 expression in skeletal muscle cells. Int. J. Biochem. Cell Biol. 44:1993-2002. http://dx.doi.org/10.1016/j.biocel.2012.07.028.
17. Oh S, Kim E, Kang D, Kim M, Kim JH, Song JJ. 2013. Transforming growth factor-beta gene silencing using adenovirus expressing TGF-beta1 or TGF-beta2 shRNA. Cancer Gene Ther. 20:94-100. http://dx.doi.org/10.1038/cgt.2012.90.
18. Echeverria C, Montorfano I, Hermosilla T, Armisen R, Velasquez LA, Cabello-Verrugio Simon F. 2014. Endotoxin induces fibrosis in vascular endothelial cells through a mechanism dependent on transient receptor protein melastatin 7 activity. PLoS One 9:e94146. http://dx.doi.org/10.1371/journal.pone.0094146.
19. Cabello-Verrugio C, Morales MG, Cabrera D, Vio CP, Brandan E. 2012. Angiotensin II receptor type 1 blockade decreases CTGF/CCN2-mediated damage and fibrosis in normal and dystrophic skeletal muscles. J. Cell. Mol. Med. 16:752-764. http://dx.doi.org/10.1111/j.1582-4934.2011.01354.x.
20. Pei Z, Lin D, Song X, Li H, Yao H. 2008. TLR4 signaling promotes the expression of VEGF and TGF-beta1 in human prostate epithelial PC3 cells induced by lipopolysaccharide. Cell. Immunol. 254:20-27. http://dx.doi.org/10.1016/j.cellimm.2008.06.007.
21. Yu L, Hebert MC, Zhang YE. 2002. TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J. 21:3749-3759. http://dx.doi.org/10.1093/emboj/cdf366.
22. Meyer-Ter-Vehn T, Gebhardt S, Sebald W, Buttmann M, Grehn F, Schlunck G, Knaus P. 2006. p38 inhibitors prevent TGF-beta-induced myofibroblast transdifferentiation in human tenon fibroblasts. Invest. Ophthalmol. Vis. Sci. 47:1500-1509. http://dx.doi.org/10.1167/iovs.05-0361.
23. Desmouliere A. 1995. Factors influencing myofibroblast differentiation during wound healing and fibrosis. Cell Biol. Int. 19:471-476. http://dx.doi.org/10.1006/cbir.1995.1090.
24. Grande MT, Lopez-Novoa JM. 2009. Fibroblast activation and myofibroblast generation in obstructive nephropathy. Nat. Rev. Nephrol. 5:319-328. http://dx.doi.org/10.1038/nrneph.2009.74.
25. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. 2002. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat. Rev. Mol. Cell Biol. 3:349-363. http://dx.doi.org/10.1038/nrm809.
26. Hippenstiel S, Soeth S, Kellas B, Fuhrmann O, Seybold J, Krull M, Eichel-Streiber C, Goebeler M, Ludwig S, Suttorp N. 2000. Rho proteins and the p38-MAPK pathway are important mediators for LPS-induced interleukin-8 expression in human endothelial cells. Blood 95:3044-3051.
27. Yan W, Zhao K, Jiang Y, Huang Q, Wang J, Kan W, Wang S. 2002. Role of p38 MAPK in ICAM-1 expression of vascular endothelial cells induced by lipopolysaccharide. Shock 17:433-438. http://dx.doi.org/10.1097/00024382-200205000-00016.
28. Zeng L, Wang G, Ummarino D, Margariti A, Xu Q, Xiao Q, Wang W, Zhang Z, Yin X, Mayr M, Cockerill G, Li JY, Chien S, Hu Y, Xu Q. 2013. Histone deacetylase 3 unconventional splicing mediates endothelial-tomesenchymal transition through transforming growth factor beta2. J. Biol. Chem. 288:31853-31866. http://dx.doi.org/10.1074/jbc. M113.463745.
29. Chin BY, Mohsenin A, Li SX, Choi AM, Choi AM. 2001. Stimulation of pro-alpha(1)(I) collagen by TGF-beta(1) in mesangial cells: role of the p38 MAPK pathway. Am. J. Physiol. Renal Physiol. 280:F495-F504.
30. Wang FM, Hu T, Tan H, Zhou XD. 2006. p38 mitogen-activated protein kinase affects transforming growth factor-beta/Smad signaling in human dental pulp cells. Mol. Cell. Biochem. 291:49-54. http://dx.doi.org/10.1007/s11010-006-9193-8.
31. Wang FM, Hu T, Zhou X. 2006. p38 mitogen-activated protein kinase and alkaline phosphatase in human dental pulp cells. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 102:114-118. http://dx.doi.org/10.1016/j.tripleo.2005.08.007.
32. De Crescenzo G, Hinck CS, Shu Z, Zuniga J, Yang J, Tang Y, Baardsnes J, Mendoza V, Sun L, Lopez-Casillas F, O'Connor-McCourt M, Hinck AP. 2006. Three key residues underlie the differential affinity of the TGF beta isoforms for the TGF beta type II receptor. J. Mol. Biol. 355:47-62. http://dx.doi.org/10.1016/j.jmb.2005.10.022.
33. Burke JP, Cunningham MF, Watson RW, Docherty NG, Coffey JC, O'Connell PR. 2010. Bacterial lipopolysaccharide promotes profibrotic activation of intestinal fibroblasts. Br. J. Surg. 97:1126-1134. http://dx.doi.org/10.1002/bjs.7045.
34. McClain JA, Phillips LL, Fillmore HL. 2009. Increased MMP-3 and CTGF expression during lipopolysaccharide-induced dopaminergic neurodegeneration. Neurosci. Lett. 460:27-31. http://dx.doi.org/10.1016/j.neulet.2009.05.044.